Hippo pathway targeting anticancer therapeutics - TYK Medicine
Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator TYK Medicine
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Solid-tumours in China
- 30 Sep 2020 Preclinical trials in Solid tumours in China (unspecified route) (TYK Medicine pipeline, September 2020)